Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model

Neoadjuvant chemotherapy has been established as the standard of care for HER2-positive breast cancer since it allows cancer down-staging, up to pathological complete response. The standard of care in the neoadjuvant setting for HER2-positive breast cancer is a combination of highly cytotoxic drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreata, F., Bonizzi, A., Sevieri, M., Truffi, M., Monieri, M., Sitia, L., Silva, F., Sorrentino, L., Allevi, R., Zerbi, P., Marchini, B., Longhi, E., Ottria, R., Casati, S., Vanna, R., Morasso, C., Bellini, M., Prosperi, D., Corsi, F., Mazzucchelli, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351752/
https://www.ncbi.nlm.nih.gov/pubmed/32651443
http://dx.doi.org/10.1038/s41598-020-68205-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351752/
https://www.ncbi.nlm.nih.gov/pubmed/32651443
http://dx.doi.org/10.1038/s41598-020-68205-w

Ejemplares similares